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Recent progress in DNA sequencing technology has made it possible to identify specific genetic mutations in familial
disorders. For example, autoinflammatory syndromes are caused by mutations in gene coding for immunoproteasomes.
These diseases include Japanese autoinflammatory syndrome with lipodystrophy, Nakajo-Nishimura syndrome, joint
contractures, muscular atrophy, microcytic anemia, panniculitis-associated lipodystrophy syndrome, and chronic atypical
neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome. Causal mutations of these syndromes
are present in gene coding for subunits of the immunoproteasome. Importantly, a genetically modified mouse
that lacks the catalytic subunit of immunoproteasomes does not always develop an autoinflammatory syndrome.
Analysis of causal gene mutations, assessment of patients’ phenotypic changes, and appropriate animal models
will be indispensable for clarifying the underlying mechanisms responsible for the development of autoinflammatory
syndromes and establishing curative approaches.
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Inflammation is caused by a variety of factors including
endogenous abnormalities, infection, and toxins and in-
volved in immune-mediated disorders including auto-
immune or autoinflammatory disorders. Autoimmune
disorders are caused by hyper-reactivity of the immune
system against self-derived antigens [1, 2]. On the other
hand, recent studies have uncovered other types of inflam-
matory pathologies termed “autoinflammation” that are
induced by activation of innate immune cells without
apparent infection or autoimmune responses. Autoin-
flammatory syndromes are hereditary diseases and
mainly caused by a mutation of a single gene that codes
for a component of NACHT, LRR, and PYD domain-
containing protein (NLRP) inflammasomes, cytosolic
DNA danger sensing machinery, cytokine receptors, and
immunoproteasomes [3–5]. However, the causal gene
mutations are unclear and/or involve multiple mutations
in some cases.
We and the other groups have reported an autoin-
flammatory syndrome in which the gene for proteasome
subunit beta-type 8 (PSMB8) has been altered [6–9]. The* Correspondence: yasutomo@tokushima-u.ac.jp
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resulting in the accumulation of ubiquitin-coupled pro-
teins. Although it is now clear that the dysregulation of
immunoproteasomes causes an autoinflammatory syn-
drome, the molecular mechanism of the inflammatory
response is unclear. Here, we discuss the recent progress
in the genetic analysis of autoinflammatory syndromes
caused by dysfunctional immunoproteasomes.Main text
Proteasomes and immunoproteasomes
The proteasome is a multi-subunit protease complex that
degrades ubiquitinated proteins in the cytosol for rapid
turnover [10, 11]. The 26S standard proteasome is com-
posed of a 19S and 20S proteasome unit. The 20S prote-
asome is formed by the 14 α subunits and the 14 β
subunits, in which β1 (coded by the PSMB6 gene), β2
(coded by PSMB7 gene), and β5 (coded by PSMB5 gene)
subunits possess protease activities. The standard prote-
asome is present in most eukaryotic cells, and the thymo-
proteasome is a specific proteasome found in the thymus
[12]. The immunoproteasome is a special proteasome
composed of β1i (coded by PSMB9), β2i (coded by
PSMB10), and β5i (coded by PSMB8) subunits instead of
the β1, β2, and β5 subunits of the standard proteasome,le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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are induced by interferon-γ stimulation. The β5i subunit
possesses strong chymotrypsin-like activity, and β1i and
β2i subunits have caspase and trypsin-like activities, re-
spectively [13]. The immunoproteasome efficiently gener-
ates peptides presented by MHC class I and degradation
of oxidized proteins to maintain cellular homeostasis [14].
Autoinflammatory syndromes with proteasome
dysfunction
Autoinflammatory diseases resulting from dysfunctional
proteasomes are termed “proteasome-associated autoin-
flammatory syndromes” (PRAAS) [15]. PRAAS include
Japanese autoinflammatory syndrome with lipodystrophy
(JASL) [7], Nakajo-Nishimura syndrome (NNS) [8],
joint contractures, muscular atrophy, microcytic anemia,
panniculitis-associated lipodystrophy (JMP) syndrome [6],
and chronic atypical neutrophilic dermatosis with lipo-
dystrophy and elevated temperature (CANDLE) syndrome
[9] (Fig. 1).
JASL is characterized by recurrent fever, nodular ery-
thema, high CRP levels, and hypergammaglobulinemia
together with a loss of adipose tissue in the upper part
of the body. Three JASL patients from 2 consanguineous
families showed high fever and severe inflammation,
although they did not possess autoantibodies or an im-
munocompromised constitution [7]. Patients with the
JMP syndrome were found in two family lines in Mexico
and Portugal. They showed hepatosplenomegaly; macro-
somia; lipodystrophy of face, arms, and chest; scleroder-
mic skin with erythematous lesions; microcytic anemia
with higher serum levels of interferon-γ, IL-8, and IL-6;
and hypergammaglobulinemia [6]. NNS is a wasting
disease seen early in life and it has been found only in
the Japanese population [8]. The patients show elongated
and thickened fingers, periodic high fever, nodular ery-
thema, lipomuscular atrophy with joint contractures,
myositis, and hypergammaglobulinemia. Cell extracts
prepared from the patients indicated that three
immunoproteasome-related protease activities were below’5
exon 1 2
PSMB8 UTR
No. 42,5
No. Disease cDNA Protein
1 JASL G1112T G197V
2 JMP syndrome C224T T75M
3 NNS G602T G201V
4 CANDLE syndrome C405A C135X; stop
5 CANDLE syndrome C224T T75M
6 CANDLE syndrome A313C K105Q
Fig. 1 Mutations in PSMB8. Causal mutations of the autoinflammatory syndnormal compared with healthy controls. CANDLE syn-
drome patients have been found in Jewish, Spanish,
Caucasian, and Hispanic populations. They also show
recurrent fevers; delayed physical development; hypochro-
mic or normocytic anemia; progressive lipodystrophy;
joint pain; and increased acute phase reactants with vari-
able clinical features, including skin hyperpigmentation,
spot alopecia, and polytrichia [9].
Causal mutations leading to JASL and other
autoinflammatory syndromes with dysfunctional
proteasomes
In a search for the causal mutation of JASL, we used
SNP homozygosity mapping, linking analysis, and exome
analysis [7]. We identified a specific mutation of the
PSMB8 gene present in chromosome 6 in patients from
2 distinct Japanese families. This mutation was homozy-
gous with a transversion of guanine to adenine with an
amino acid change from glycine to valine at a position of
197 (p.G197V) of the PSMB8 protein. The original amino
acid has been conserved across animal species, suggesting
an important role of this amino acid in the maintenance
of form and function of the protein.
NNS, JMP, and CANDLE syndromes are also caused
by mutations in the PSMB8 gene, although different re-
gions are involved [6, 8, 9]. Agarwal et al. found a
homozygous missense mutation of C to T at position
224 (c.C224T) in the PSMB8 gene, resulting in a p.T75M
change in JMP patients [6]. Arima et al. reported that the
causal mutation of NNS is a p.G201V mutation in PSMB8
exon 5 [8] and Liu and co-workers described one patient
with the CANDLE syndrome who possessed a homozy-
gous nonsense mutation at position 405 resulting in a C
to A change with a protein truncation. Four others were
homozygous and two others had a heterozygous missense
mutation at c.C224T. In a Caucasian patient, no mutation
in the PSMB8 gene was found [9]. Recently, new muta-
tions related to the CANDLE syndrome were identified in
the PSMA3 gene coding α7, PSMB4 coding β7, and
PSMB9 coding β1i as well as PSMB8 and proteasome’3
3 4 65
,6 1,3
UTR
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One patient had two heterozygous PSMB4 gene muta-
tions that were c.G(-9)A. in the 5′ UTR and a 9-bp in-
frame deletion caused p.D212_V214del. Other PSMB4
mutations were heterozygous variants c.44insG/p.P16Sfs*45
found in a Jamaican patient and a monoallelic nonsense
mutation c.C666A/p.Y222X found in an Irish patient. The
mutations in PSMA3 found in two unrelated patients were
heterozygous 3-bp in-frame deletions (c.696_698delAAG/
p.R233del) and c.T(404+2)G/p.H111Ffs*10 at the splicing
site. The mutation in PSMB9 was a missense substitution
(c.G494A) and affected a conserved amino acid residue
(p.G165D). A newly identified PSMB8 mutation was a
heterozygous missense mutation of c.A313C/p.K105Q
in an Irish patient. A mutation in the POMP gene of a
Palestinian patient was a heterozygous frameshift muta-
tion, c.344_345insTTTGA/p.E115Dfs*20. Another muta-
tion in the PSMB8 gene resulted in a p.Q49K change that
was found in patients of juvenile rheumatoid arthritis that
had some clinical features similar to NNS [17].Effects of PSMB8 protein abnormality on cellular physiology
and animal disease models
Mutations found in the PSMB8 gene from autoinflam-
matory syndrome patients can affect the PSMB8 protein
and immunoproteasome functions. The G201V mutation
found in NNS patients affects both the proteolytic activity
of β5i and the assembly of the immunoproteasome. These
conclusions are based on the observation that an accu-
mulation of immature 20S proteasome precursors was
found in NNS cells [7]. Immortalized lymphoblasts de-
rived from a JMP patient showed reduced chymotrypsin-
like activity without an effect on trypsin-like or caspase-
like activity. Brehm et al. described hematopoietic and
non-hematopoietic cells derived from CANDLE patients
who had different types of mutations, including those
leading to abnormal protein expression, protein folding,
proteasome assembly, proteasome activity, and strong
type 1 IFN expression [16]. Immortalized transformed B
cells from a JASL patient showed lower expression of
PSMB8 at the mRNA and protein levels, and the activities
of caspase-like, trypsin-like, and chymotrypsin-like prote-
ases in cell extracts were decreased compared with healthy
control samples [7]. The reduced expression of mature
PSMB8 protein was also confirmed in the skin of a JASL
patient. Immature proteasomes were increased in JASL
cells, indicating that the immunoproteasome assembly
was defective in the mutant cells. Consistent with these
data, ubiquitinated proteins were increased in cell extracts
of transformed cells and the skin of a JASL patient. IL-6
expression in the skin of the patient and cells carrying
mutant PSMB8 proteins were increased via p38 MAP
kinase signaling [7]. Kasagi et al. also reported serum IL-6levels in JASL patients were higher than those of healthy
controls [18].
PSMB8 knockout mice grow normally and no spon-
taneous inflammation is observed, unlike patients with
dysfunctional proteasome syndromes. Seifert et al. reported
that β5i-deficient mice showed symptoms of experimental
allergic encephalomyelitis [14]. However, it has been re-
ported that PSMB8 deletion or treatment with its specific
inhibitor suppresses autoreactive immune responses in
murine models of arthritis, diabetes [19], experimental
colitis [20], Hashimoto’s thyroiditis [21], and lupus-like
disease [22]. These suppressive effects may relate to the
ability of β5i-deficient or specific inhibitor-treated cells
to diminish Th1, Th2, and Th17 differentiation and en-
hance regulatory T cell differentiation [23]. The produc-
tion of IL-23 by activated monocytes and IFN-γ and IL-2
by activated T cells is also blocked by treatment of the
cells with a selective inhibitor of β5i [24]. Therefore, to
determine how missense mutations in PSMB8 cause in-
flammatory responses in human, it will be necessary to
establish mice that harbor a mutation in the PSMB8
gene.
Conclusions
Improvements in genotyping efficiency, sequencing tech-
nology, and statistical methodology have made it pos-
sible for researchers to identify specific gene mutations
associated with autoinflammatory syndromes. Some mu-
tations and polymorphisms connected to dysregulated
proteasome syndromes have been reported, but the func-
tional consequences of genetic variations are not fully
understood. To increase our understanding of the patho-
physiology of these diseases, basic and advanced studies
with tissues from patients and genetically modified animals
will be required to determine how the mutations affect
cellular physiology and proteasome function. Analysis
of causal gene mutations, the subsequent phenotypic
changes in autoinflammatory syndrome patients, and
establishment of a proper animal model for these dis-
eases will be indispensable to clarify the mechanisms of
autoinflammatory syndrome development and to develop
cures for these diseases.
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